Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced an agreement with KaloBios Pharmaceuticals for the development of a Humaneered™ antibody fragment to both treat and prevent Pseudomonas aeruginosa (Pa) infections.
Under the terms of the agreement, Sanofi Pasteur acquires worldwide rights to KaloBios’ technology for all disease indications related to Pa infections except cystic fibrosis and bronchiectasis, which Sanofi Pasteur has the option to obtain at a later date. KaloBios has already completed phase I clinical trials - one in healthy volunteers and one in cystic fibrosis patients - and a small proof of concept phase II clinical trial in mechanically ventilated patients.
“KaloBios has shown convincing safety data in phase I studies and a trend toward efficacy in a phase II study of ventilator-associated pneumonia,” declared Wayne Pisano, President and CEO of Sanofi Pasteur. “Hospital-acquired Pa infections are associated with very high levels of morbidity, mortality and costs and treating them represents a significant, unmet medical need. Despite modern antibiotic therapy, treatment failures, relapses and deaths are common,” said Pisano.
The two primary target indications for the antibody are prevention of Pa associated pneumonia in mechanically ventilated patients in hospitals as well as prevention of relapses and potential improvement of treatment outcomes in patients with an ongoing Pa infection. Additional indications - both prophylactic and therapeutic - can be considered later in the lifecycle of the product.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
More than skin deep
PSR-Agility Wins Second Consecutive ROAR Award for “Best Orphan Drug CRO” - Continued recognition by industry and non-industry experts as unique partner in Orphan Drug Development
Part of hagfish slime mystery solved

Effects of chemical mixtures: Neurotoxic effects add up - Study demonstrates for the first time the toxicological relevance of chemical mixtures as they occur in humans

Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding

Shifting meetings, conventions online curbs climate change - The annual carbon footprint for the global event and convention industry is on par with the yearly greenhouse gas emissions of the entire U.S.
Photocure announces positive results of Phase 2B study evaluating Visonac in acne
Dental_porcelain
Rockeby awarded bird flu tests tender from Middle East
Rentschler focuses on biotechnology

How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings
